Li Xutong, Chai Jie, Wang Zhi, Lu Lin, Zhao Qingye, Zhou Jie, Ju Fang
Department of Oncology, Second Affiliated Hospital, Qingdao University, Qingdao, Shandong 266042, People's Republic of China,
Department of MRI, Second Affiliated Hospital, Qingdao University, Qingdao, Shandong 266042, People's Republic of China.
Onco Targets Ther. 2018 Jul 30;11:4407-4411. doi: 10.2147/OTT.S166605. eCollection 2018.
Reversible posterior leukoencephalopathy syndrome (RPLS) is a rare clinical-radiologic syndrome. There are reports that RPLS may be associated with cancer therapy including some chemotherapy drugs and antiangiogenic drugs. This paper reported a case of RPLS induced by apatinib, a vascular endothelial growth factor receptor 2 (VEGFR-2) tyrosine kinase inhibitor. A 47-year-old cervical cancer patient was administered apatinib, and 3 months later, headache, dizziness, blurred vision, and hypertension appeared. She was diagnosed with RPLS by nuclear magnetic resonance imaging (MRI). After apatinib discontinuation and normotensive treatment, her symptoms completely reversed. Antiangiogenic drugs potentially damage the balance of the blood-brain barrier by directly injuring vascular endothelial cells, resulting in the occurrence of RPLS. This case is the first report of RPLS induced by apatinib.
可逆性后部白质脑病综合征（RPLS）是一种罕见的临床-放射学综合征。有报道称，RPLS可能与癌症治疗相关，包括某些化疗药物和抗血管生成药物。本文报告了1例由血管内皮生长因子受体2（VEGFR-2）酪氨酸激酶抑制剂阿帕替尼诱发的RPLS病例。1例47岁宫颈癌患者接受阿帕替尼治疗，3个月后出现头痛、头晕、视力模糊和高血压。通过核磁共振成像（MRI）诊断为RPLS。停用阿帕替尼并进行降压治疗后，其症状完全缓解。抗血管生成药物可能通过直接损伤血管内皮细胞破坏血脑屏障的平衡，从而导致RPLS的发生。该病例是阿帕替尼诱发RPLS的首例报道。
